IL17A and psoriasis: Currently, biologics targeting TNF, IL-17, and IL-12/23, including etanercept, adalimumab (ADA), secukinumab (SEC), ixekizumab (IXE), brodalumab, stekinumab, and guselkumab, are widely used in clinical practice for managing psoriasis [8].